Clinically, targeting sEV‐NAMPT with the inhibitor FK866 significantly inhibited tumour growth in various HCC in vivo models, highlighting the potential of sEV‐NAMPT as both a biomarker and therapeutic target in HCC. Here, NAMPT is linked to hepatocellular carcinoma.